Related Experiment Video

Updated: Apr 17, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K

Activin receptor inhibitors--dalantercept

Shilpa Gupta1, David Gill, Sumanta K Pal

  • 1H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA, Shilpa.Gupta@moffitt.org.

Current Oncology Reports
|February 25, 2015
PubMed

Insights

Dalantercept targets bone morphogenetic proteins (BMP 9 and BMP 10) to inhibit new blood vessel formation in tumors. This novel anti-angiogenic therapy offers a potential alternative for cancers resistant to current treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) have improved cancer survival but often face resistance.
  • Tumor resistance to anti-VEGF agents necessitates exploring novel therapeutic targets and pathways.
  • The bone morphogenetic proteins (BMP 9 and BMP 10) pathway, activating activin receptor-like kinase-1 (ALK1), is implicated in vascular development and represents a potential target.

Purpose of the Study:

  • To review the preclinical and clinical development of dalantercept (ACE-041) as a novel anti-angiogenic agent.
  • To discuss dalantercept's mechanism of action, targeting BMP 9 and BMP 10 via ALK1.
  • To evaluate dalantercept's safety profile and efficacy in various cancers, including combination therapies.

Main Methods:

  • Review of preclinical studies investigating dalantercept's anti-angiogenic effects.
  • Analysis of clinical trial data assessing dalantercept's safety and efficacy in cancer patients.
  • Examination of studies exploring combination strategies with other anti-VEGF therapies.

Main Results:

  • Dalantercept acts as a ligand trap for BMP 9 and BMP 10, inhibiting ALK1 signaling and disrupting tumor vascularization.
  • Preclinical and clinical data suggest dalantercept has a distinct safety profile compared to traditional anti-VEGF agents.
  • Ongoing studies are evaluating dalantercept's potential in combination with other cancer treatments.

Conclusions:

  • Dalantercept represents a promising novel anti-angiogenic therapy targeting the BMP/ALK1 pathway.
  • It offers a potential treatment alternative for patients with resistance to existing anti-angiogenic therapies.
  • Further clinical investigation, including combination studies, is warranted to establish its full therapeutic potential.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
577
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
622
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K